Spectrum Pharmaceuticals, Inc. Sustainability Profile
Spectrum Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2000, the company has established itself as a leader in the development of innovative therapies for cancer and other serious diseases. With a focus on oncology, Spectrum Pharmaceuticals is dedicated to providing unique and effective treatment options that address unmet medical needs. The company’s core products include a range of targeted therapies and supportive care medications, which are distinguished by their commitment to improving patient outcomes. Spectrum has achieved significant milestones, including the successful launch of several key products that have garnered attention in the market. With a strong presence in the US and expanding operations in international markets, Spectrum Pharmaceuticals continues to solidify its position as a trusted name in the fight against cancer.
DitchCarbon Score
How does Spectrum Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Spectrum Pharmaceuticals, Inc.'s score of 25 is lower than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Spectrum Pharmaceuticals, Inc.'s reported carbon emissions
Spectrum Pharmaceuticals, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Assertio Holdings, Inc., which may influence its climate-related initiatives and reporting practices. As of now, Spectrum Pharmaceuticals has not established any documented reduction targets or commitments to the Science Based Targets initiative (SBTi). This lack of specific climate pledges suggests that the company may still be in the early stages of developing a comprehensive sustainability strategy. Given the absence of direct emissions data and reduction initiatives, it is essential for Spectrum Pharmaceuticals to consider adopting industry-standard climate commitments to enhance its environmental performance and align with global sustainability goals.
How Carbon Intensive is Spectrum Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Spectrum Pharmaceuticals, Inc.'s Location?
Spectrum Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Spectrum Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
